EHR-Based Marker Flags Transplant Patients at Risk of Organ Rejection

Why It Matters

Early detection of nonadherence enables clinicians to intervene before rejection, improving graft survival and reducing costly hospitalizations across the transplant ecosystem.

Key Takeaways

• MLVI uses routine immunosuppressant blood level variability
• Flags adolescent and young adult liver transplant patients
• Identifies nonadherence risk before clinical rejection occurs
• Utilizes existing EHR data, no extra testing required
• Supports proactive interventions, potentially improving graft survival

Pulse Analysis

Medication adherence remains a chronic challenge in solid‑organ transplantation, especially among adolescents and young adults who face lifestyle transitions and psychosocial pressures. Non‑adherence contributes to up to 30% of acute rejection episodes, driving higher morbidity, readmission rates, and long‑term healthcare expenditures. By pinpointing patients at risk before clinical signs emerge, providers can allocate resources—such as counseling, digital reminders, or home health visits—more efficiently, ultimately preserving graft function and reducing the financial strain on hospitals and insurers.

The Medication Level Variability Index (MLVI) quantifies fluctuations in immunosuppressant trough concentrations over time, translating raw lab values into a risk score that fits seamlessly within existing electronic health record workflows. In the recent multicenter RCT, MLVI identified non‑adherent liver transplant recipients with a sensitivity surpassing traditional self‑report measures, without requiring additional laboratory draws or invasive monitoring. Because the algorithm leverages data already captured during routine care, implementation costs are minimal, and the approach can be automated through clinical decision support alerts, prompting transplant teams to intervene promptly.

Beyond liver transplants, the MLVI framework offers a template for broader organ‑specific adherence monitoring, potentially extending to kidney, heart, and lung recipients. Health systems that adopt this EHR‑based marker can expect earlier therapeutic adjustments, fewer rejection‑related admissions, and improved long‑term outcomes, aligning with value‑based care initiatives. Future research may integrate MLVI with wearable adherence technologies and predictive analytics, creating a comprehensive ecosystem that transforms raw lab data into actionable insights for transplant clinicians worldwide.